Industry Update: Cannabidiol On the Road to FDA Approval video

Justin Gover, CEO of GW Pharmaceuticals, the parent company of Greenwich Biosciences, provides an update on the status of Epidiolex(R), GW’s cannabidiol product, after positive results from several controlled trials were presented at the 2016 American Epilepsy Society Annual Meeting in Houston, TX.

Go here to read about positive trial results for cannabidiol in Lennox-Gastaut and Dravet syndrome: http://www.neurologyadvisor.com/aes-2016-coverage/cannabidiol-helps-reduce-frequency-of-drop-seizures-in-lennox-gastaut-syndrome/article/576842/
http://www.neurologyadvisor.com/aes-2016-coverage/cannabidiol-reduces-seizure-frequency-in-refractory-dravet-syndrome/article/576878/

For more coverage of AES 2016, go here: http://www.neurologyadvisor.com/aes-2016-coverage/section/7080/

Likes: 1.

This video clip has been viewed: 564 times and provides a duration of 00:02:52 seconds.